The biotech sector focuses on developing innovative medical treatments using biological processes. These companies research and create new drugs, therapies, and medical devices. Biotech stocks represent ownership in these cutting-edge firms. The sector is known for its potential to revolutionize healthcare and generate significant returns. However, it’s also associated with high risk due to the complex nature of drug development.Investing in biotech stocks can offer several advantages. These stocks have the ...

Would a stock split help lead Regeneron Pharmaceuticals shares higher?Regeneron Pharmaceuticals (REGN -1.00%) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price, making it more accessible to investors who can't buy fractional shares, or who simply don't want to do so. It would also give the stock some great, positive free press, which could potentially lead to even more of a rally.Should investors expect ...

PM Images Regeneron's Q2 Surge: Blockbuster Drugs Drive Revenue Growth Regeneron (NASDAQ:REGN) is up another 13% since my most recent "buy" recommendation in March. Seeking Alpha My last article covered Q4 '2023 earnings, which revealed strong performances from blockbuster drugs like Eylea, Libtayo, and Dupixent. In Q2 2024, it was more of the same for the $100 billion-plus pharmaceutical giant. Revenue grew 12% year-over-year, reaching $3.55 billion. The growth was, again, inspired by strong performances f ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conf ...

Regeneron (REGN) reported $3.55 billion in revenue for the quarter ended June 2024, representing a year-overyear increase of 12.3%. EPS of $11.56 for the same period compares to $10.24 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.38 billion, representing a surprise of +4.84%. The company delivered an EPS surprise of +9.37%, with the consensus EPS estimate being $10.57. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Regeneron Pharmaceuticals, Inc. (REGN) reported earnings per share (EPS) of $11.56, which beat the Zacks Consensus Estimate of $10.57. The company recorded an EPS of $10.24 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Total revenues increased 12% year over year to $3.54 billion, fueled by higher Dupixent, Eylea HD and Libtayo sales. Revenues also beat the Zacks Consensus Estimate of $3.38 billion. Shares are trading up in response to the better-than-expected resu ...

Regeneron (REGN) came out with quarterly earnings of $11.56 per share, beating the Zacks Consensus Estimate of $10.57 per share. This compares to earnings of $10.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.37%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $10.20 per share when it actually produced earnings of $9.55, delivering a surprise of -6.37%.Over the last four quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3 ...

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2024 Financial and Operating Results • Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023 • Second quarter 2024 Dupixent global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023 • Second quarter 2024 U.S. net sales for EYLEA HD and EYLEA increased 2% to $1.53 billion versus second quarter 2023, including $304 million from EYLEA HD • Second quarter 2024 Libtayo global net sal ...

Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023Second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second quarter 2023Second quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® increased 2% to $1.53 billion versus second quarter 2023, including $304 million from EYLEA HDSecond quarter 2024 Libtayo® global net sales increased 42% to $297 million versus second quarter 2023Second quarter 2024 GAAP diluted EPS increase ...